Evidence map›Paper›PMID 35862965›Full record

ArticleMicrobiology spectrum2022

Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells.

Takanari Hattori, Takeshi Saito, Kosuke Okuya, Yuji Takahashi, Hiroko Miyamoto, Masahiro Kajihara, Manabu Igarashi, Ayato Takada

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Takanari HattoriDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Takeshi SaitoDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Kosuke OkuyaDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.ORCID 0000-0002-7987-9884
Yuji TakahashiDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Hiroko MiyamotoDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Masahiro KajiharaDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Manabu IgarashiDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Ayato TakadaDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Hokkaido University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 have a single envelope glycoprotein (S protein) that binds to human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane. Previous mutational scanning studies have suggested that some substitutions corresponding to single nucleotide variants (SNVs) in human ACE2 affect the binding affinity to the receptor binding domain (RBD) of the SARS-CoV-2 S protein. However, the importance of these substitutions in actual virus infection is still unclear. In this study, we investigated the effects of the reported ACE2 SNV substitutions on the entry of SARS-CoV and SARS-CoV-2 into cells, using vesicular stomatitis Indiana virus (VSIV) pseudotyped with S proteins of these coronaviruses (CoVs). HEK293T cells transfected with plasmids expressing ACE2 having each SNV substitution were infected with the pseudotyped VSIVs and relative infectivities were determined compared to the cells expressing wild-type ACE2. We found that some of the SNV substitutions positively or negatively affected the infectivities of the pseudotyped viruses. Particularly, the H505R substitution significantly enhanced the infection with the pseudotyped VSIVs, including those having the substitutions found in the S protein RBD of SARS-CoV-2 variants of concern. Our findings suggest that human ACE2 SNVs may potentially affect cell susceptibilities to SARS-CoV and SARS-CoV-2.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19HEK293 CellsHumansPolymorphism, GeneticProtein BindingReceptors, VirusSARS-CoV-2Severe acute respiratory syndrome-related coronavirusSpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Receptors, VirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2polymorphismSARS-CoVSARS-CoV-2SNPsSNVsspike proteinviral entry

Identifiers

PMID35862965
PMCPMC9430119
OpenAlexW4285014180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.